NurExone Biologic Inc.
Developing biologically guided exosome therapies for central nervous system injuries.
Live Chart
TSXV:NRX.V — Real-time price data
Investor Insight
Why this opportunity matters now
NurExone Biologic Inc. is a biopharmaceutical innovator advancing a proprietary, non-invasive exosome platform ('ExoTherapy') for central nervous system (CNS) injuries and neurological regeneration.
Supported by Orphan Drug Designations from both the U.S. FDA and European Medicines Agency (EMA) for its lead drug candidate, ExoPTEN, NurExone is progressing toward first-in-human clinical trials. The company's platform model offers dual upside through proprietary biopharmaceutical development and near-term commercial revenue via naïve exosome production and licensing through its U.S. subsidiary, Exo-Top Inc.
Company Overview
Who NurExone Biologic Inc. is and what they do
NurExone Biologic Inc. (TSXV: NRX) is a pharmaceutical technology company headquartered in Toronto, Canada, with scientific operations in Israel. The company develops off-the-shelf, targeted exosome-based therapeutics engineered to promote nerve regeneration and functional recovery in patients with traumatic spinal cord injury, optic nerve damage, and facial nerve conditions.
Through exclusive worldwide licenses from the Technion - Israel Institute of Technology and Tel Aviv University, NurExone leverages membrane-bound extracellular vesicles loaded with active therapeutic agents, such as siRNA, to cross biological barriers and deliver targeted treatment via simple intranasal administration.
Company Highlights
Key competitive advantages at a glance
Key Assets
The flagship project driving value
ExoPTEN Therapy
ExoPTEN is NurExone's flagship therapeutic candidate, composed of MSC-derived exosomes loaded with a proprietary PTEN-inhibiting siRNA sequence. Administered intranasally shortly after spinal cord trauma, ExoPTEN delivers siRNA directly to injured spinal tissue to suppress PTEN expression, enabling axon regrowth, structural repair, and functional motor rehabilitation.
Management Team
Experienced leadership driving results
Leadership Team in Biotechnology, R&D, and Corporate Finance
Dr. Lior Shaltiel
Biotech executive with broad experience leading R&D, corporate development, and technology commercialization in life science companies.
ProfileDavid Stolick
Experienced corporate governance and executive leader serving on the board of directors.
ProfileLatest News
Recent coverage and market updates
Modular Manufacturing Strategy and Commercial Growth
Disrupting the Exosome Industry: Syed T. Husain and Yoram Drucker on Manufacturing at Scale
NurExone Advances Optic Nerve Injury Program Toward Larger-Animal Study, Following Positive Preclinical ResultsPreclinical Results at Sheba Medical Center Demonstrate Retinal Recovery with NurExone’s Exosome-based Lead Candidate
US$90 Billion by 2030: How Bayer, Mesoblast and NurExone Are Developing Regenerative Medicine Differently
NurExone Expands U.S. Engagement Across Four Major Boston Life Sciences Events and Provides Corporate Update
NurExone Biologic: ExoPTEN and ExoTop, Advancing in Parallel (TSXV: NRX | OTCQB: NRXBF )
NurExone and NanoPass Technologies Ltd. to Collaborate on Integrated Exosome Delivery Approach for Regenerative Eye and Skin Applications
